Document is current

Article History

Received: 17 December 2021

Accepted: 26 September 2022

First Online: 8 October 2022

Declarations

:

: All methods in the described trial were performed in accordance with the Declaration of Helsinki and other relevant guidelines and regulations. The study was approved by the Western Institutional Review Board (WIRB Study No.: 1090116). All subjects provided written informed consent to participate in the study.

: Not applicable.

: JSP, MB, CH, JY, KR, AK, MH, CM, AL, KC, and MS are or were employees, directors/officers, or consultants for Ocuphire Pharma. JP, EL, and MM are on the medical advisory board for Ocuphire Pharma. MM was the principal investigator for this clinical trial funded by Ocularis Pharma (now Ocuphire Pharma). JSP reports personal fees from Acufocus, Kala Pharmaceuticals, Keeler, MG Therapeutics, Mimetogen Pharmaceuticals, Novartis, Ocunexis Therapeutics, Okogen, Stuart Pharmaceuticals, Sun Pharma, Thea Pharma, TearLab, and Ocuphire. MM reports personal fees from Allergan, Alcon, Bausch and Lomb, Eyevance, Novartis, Tarsus, Visus, Aperta, Ocusoft, OCULUS USA, DOMPE, BioTissue, BlephEx, Akorn, Quidel, ORCA Surgical, TearLab, J&J Vision, TearCare, NuLids, Ocuphire, STROMA, Hellas LTD, Sun Pharma, Avedro, Omeros, Scope, and Sight Sciences. The authors indicated that they have no other conflicts of interest with regard to the content of this article.